Discounted Zoetis price offers buing opportunity, says Argus

Argus keeps a Buy rating and $200 price target on Zoetis. The company is the largest pure-play animal health and vaccine company as well as the market leader in revenue, and this industry has solid long-term growth potential, the analyst tells investors in a research note. The stock has also recently fallen significantly from its recent highs but continues to trade in a long-term pattern of higher highs, the firm added.